SurfWax News Index  |  Track News  |  Save/Exchange Information |  WikiWax |  About Us News and Articles on ICOS Corporation (ICOS)   CBS Marketwatch Quote Chart Yahoo! Finance: Profile Key Statistics SEC Filings MSN Money Earnings Estimates Financial Results Insider Trading   Amylin Comments on RiskMetrics Report  May 16, 2009 Importantly, Amylin's Board and management team have recognized and embraced the need for change, with two new independent Director nominees, Paul N. Clark, former Chairman, Chief Executive Officer and President of Icos Corporation, and Paulo F. Costa, former President and Chief Executive Officer of Novartis U.S. Corporation. Both bring additional commercial and operational expertise in the biopharmaceutical industry, which are key attributes requested by our shareholders. (PR Newswire) Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments  Apr 3, 2009 The two new independent nominees to our Board are Paul N. Clark, former Chairman, Chief Executive Officer and President of Icos Corporation, and Paulo F. Costa, former President and Chief Executive Officer of Novartis U.S. Corporation. Both possess valuable commercial and operational expertise in the biopharmaceutical industry, enhancing the existing strengths of the Board, and both are widely respected leaders who we look forward to having on the Amylin team. (PR Newswire) Implicit Licenses Clinical Stage Antibody Program From Lilly  Feb 25, 2009 IC14 had earlier been in development for severe sepsis at Icos Corporation which was acquired by Lilly in 2007. It has been used in the treatment of more than 150 patients, and has well characterized safety and pharmacology profiles. (PR Newswire) Back to Company News News [ Terms Of Use | Privacy | About ] ©1998-2006 SurfWax, Inc. All rights reserved. Patents pending. Copyright SurfWax, Inc. 2006